Private Wealth Asset Management’s Biogen BIIB Stock Holding History

Private Wealth Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2K	Hold	61	–	–	﹤0.01%	668
2026 Q1	$11.2K	Sell	61 -2	-3%	-$369	﹤0.01%	679
2025 Q4	$11.1K	Hold	63	–	–	﹤0.01%	651
2025 Q3	$8.82K	Hold	63	–	–	﹤0.01%	669
2025 Q2	$7.91K	Hold	63	–	–	﹤0.01%	705
2025 Q1	$8.62K	Buy	+63	New	+$9.01K	﹤0.01%	650

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Private Wealth Asset Management's BIIB Position: Q2 2026 in Review

Private Wealth Asset Management held its Biogen (BIIB) position steady in Q2 2026 at 61 shares worth $13.2K. The position accounts for ﹤0.01% of the portfolio, ranked #668.

Private Wealth Asset Management first reported a position in BIIB in Q1 2025 and has held it in 6 quarters since. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Private Wealth Asset Management held 61 shares of Biogen worth $13.2K as of Q2 2026.
Private Wealth Asset Management left its Biogen share count unchanged in Q2 2026.
Biogen made up ﹤0.01% of Private Wealth Asset Management's portfolio in Q2 2026, its #668 holding.
Private Wealth Asset Management first reported a position in Biogen in Q1 2025 and has held it in 6 quarters since.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Private Wealth Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.